Parexel principles for artificial intelligence (AI)

Parexel is committed to the development of innovative, high-value, high-quality use cases for AI. We believe AI provides tools to help manage the increasing complexity of clinical development, including opportunities to expedite development timelines for products to reach patients quicker.

Here we outline our six principles for how Parexel conceives, develops, deploys, and monitors AI applications intended for use in clinical development and throughout our business.


Open PDF

Return to Insights Center

Related Insights

Blog

AI Milestones: FDA’s ISTAND program accepts AI-based assessment tool for depression

Mar 19, 2024

Blog

Digital Biomarkers – The Future of Precision Medicine

Jul 21, 2022

Blog

PBPK modeling solutions as a potential risk mitigation strategy for pH dependent DDIs

Mar 15, 2021

Blog

Putting AI to work in your safety program

May 21, 2021

Blog

RBQM is our future: Using holistic risk-based oversight, we can focus on a trial’s most critical factors

Jun 18, 2021

Article

Tencent-Backed Wedoctor Is Going Public: What Are the Next Steps for Chinese Digital Health Companies?

Jun 30, 2021

Article

Evidence Generation Strategy under Germany’s Digital Healthcare: Is More Better?

Aug 6, 2021

Blog

Highlights from ISMPP Asia Pacific Meeting 2021

Sep 20, 2021

Blog

Capitalizing on sensors in clinical trials

Sep 20, 2021

Blog

Actigraphy advances a patient-first approach: Reduce patient burden — and make the most of valuable data

Oct 15, 2021

Blog

Clinical pharmacology, modeling and simulation to support FIH study design

Oct 21, 2021

Blog

CNS Summit Recap: The Future is Collaborative

Nov 22, 2021